RecruitingPhase 1Phase 2NCT07208773

A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors

A Multi-center, Open-label, Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Preliminary Efficacy of YL201 in Combination With Ivonescimab in Patients With Advanced Solid Tumors

Sponsor

MediLink Therapeutics (Suzhou) Co., Ltd.

Enrollment

260 participants

Start Date

Oct 29, 2025

Study Type

INTERVENTIONAL

Conditions

Advanced Solid Tumors

Summary

This study was designed to evaluate the efficacy and safety of YL201 in combination with Ivonescimab (AK112) in subjects with solid tumor.

Eligibility

Min Age: 18 Years

Inclusion Criteria3

Age ≥ 18 years old.
ECOG PS score is 0 or 1.
Within 7 days before the first dose, the functions of body organs and bone marrow meet the requirements.

Exclusion Criteria10

Suitable for local curative treatment.
Have received previous treatment with drugs targeting B7-H3 (including antibodies, ADCs, CAR-T, and other drugs).
Have received previous treatment with topoisomerase I inhibitors or ADCs containing topoisomerase I inhibitors.
Have experienced grade ≥ 3 irAEs during previous treatment with anti-programmed death receptor (ligand) \[anti-PD-(L)1\] or other immune checkpoint inhibitors.
History of bleeding tendency or coagulation disorders and/or clinically significant bleeding symptoms or risks within 4 weeks before randomization.
Imaging studies during the screening period show that the patient has the Imaging-confirmed tumor invasion of major blood vessels.
Active autoimmune disease requiring systemic treatment.
Brain metastases or spinal cord compression.
Patients with uncontrolled or clinically significant cardiovascular diseases.
Clinically significant concurrent pulmonary diseases.